Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Synergetic Tissue Research
12 These outcomes are consistent with a maintained postprandial metabolic effect but note the important confound: in these trials cagrilintide is almost always studied with semaglutide, so cleanly attributing the postprandial glucose benefit to cagrilintides gastric or glucagon effects specifically is not straightforward
First, we emulated the two cardiovascular outcome trials SUSTAIN-6 (semaglutide versus placebo) and SURPASS-CVOT (tirzepatide versus dulaglutide) using the RCT-DUPLICATE approach to benchmark findings and inform the study design and analytic approach for expanded questions
Craig Mortensen, DC, IFMCP, QME, IFM-Certified Functional Medicine Physician and founder of Premier IFM in Placentia, CA, serving patients throughout Orange County and Southern California.
US$ 26.54
US$ 24.57
US$ 22.51
